Articles On ImpediMed (ASX:IPD)

In 2024 several ASX medtech companies have upcoming catalysts as they strive to innovate healthcare  Primary results of EBR’s SOLVE trial expected to be published in a leading peer reviewed journal in coming months ImpediMed is focusing in...

ASX health stock fall in past five days in line with broader markets as economic and geopolitical factors weigh heavily ResMed falls as Eli Lily reports positive Phase 3 results of weight-loss drug in obese people with obstructive sleep ap...

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.091% to 7,605.60. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spot...

Provaris Energy has seen its directors strongly support its recent placement  Greentech Metals executive director sees bear lithium market as chance to buy up New board directors of ImpediMed show their confidence in growth prospects of bi...

New ImpediMed leadership team and board committed to company’s success  Private payor and Medicare coverage for SOZO device reaches critical mass in 16 US states ImpediMed prioritises 11 US states for growth as looks to boost sales and ach...

ASX health sector lifts in line with broader markets as reporting season comes to end Morgans upgrades Polynovo as total revenue rises 65.6% on pcp to $48.8 million  Nanosonics cites hospital budgetary pressures as deferring purchasing dec...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ABG)) - Abacus Group ((ABC)) - Adbri ((AHL)) - Adrad ((AMX)) - Aerometrex ((ALU)) - Altium ((AWC)) - Alumina Ltd ((ATG)) - Articore Group ((ANG)) - Austin Engineering ((...

ASX health sector falls broader market with some key names ailing in reporting season CSL Phase III trial fails to meet primary efficacy endpoint but delivers solid H1 FY24 results Neuren Pharmaceuticals falls 13% on Friday after short sel...

ASX health sector up in line with broader market but some names ail after quarterly results Cochlear lifts net profit guidance for FY24 after stronger than expected first half sales revenue  CSL to report half year results next week with b...

ASX health stocks flat in past five days in line with broader markets  Avita lowers full year 2023 guidance after slower progress in its customer’s VAC processes EBOS decides against acquisition of animal care business, reportedly Greencro...

After early gains, ASX200 finished off the day pretty even – up only .13 of a per cent.  Energy stocks led the gainers, up 1.4 per cent, fuelled by news the Organisation of Petroleum Exporting Countries (OPEC) is looking to cut output to...

Two ASX All Ords shares announced significant changes among their top brass today. And investors reacted by hitting the sell button. While the All Ordinaries Index (ASX: XAO) is up 0.2% at the time of writing, both All Ords shares are in t...

ASX to open higher on Monday after Wall Street’s third straight weekly gains ChargePoint tumbled -35pc, while GAP surged over 30pc And which are the most innovative companies in the world?   Aussie shares are poised to open higher on Mond...

ImpediMed makes leadership and board changes to enhance growth and manage costs effectively Rick Valencia will step down from his role as Managing Director and CEO effective immediately Dr. Parmjot Bains takes on the role of Interim C...

At the $240 million Perennial Better Future Trust, healthcare stocks are a critical component of our ESG-focused portfolio. These stocks, many of which have global reach, have the potential to generate attractive returns while shaping a bet...

ASX health stocks rise in past five days in line with broader markets Mach7 Technologies reports record quarterly sales orders for Q1 FY24 Aroa maintains FY24 revenue growth forecast at 30% after strong Q2 Healthcare and life sciences exp...

The Australian stock market has surged around midday, buoyed by the positive performance on Wall Street, amid growing optimism that the Federal Reserve might have concluded its series of interest rate hikes. At noon, the S&P/ASX 200 is...

  To register for today's webinar click here. Findi (ASX:FND) has extended the existing State Bank of India contract until 30 September 2024. Commenting on the SBI contract extension, Findi Chairman Mr Nicholas Smedley said: “The SBI contra...

03 Nov 2023 - A snapshot of the stocks on the move, featuring Findi (ASX:FND), Immutep (ASX:IMM) and ImpediMed (ASX:IPD).

ASX health sector falls in line with broader markets as macroeconomic factors continue to create volatility Dimerix soars on $230m licensing deal with ADVANZ PHARMA for DMX-200 into rare kidney disease US FDA approves Cyclofarm’s lung imag...

Bod Science confirm the effectiveness of Aqua Phase technology ImpediMed announces new chief medical officer   Bod Science set to commercialise Aqua Phase Cannabis focused biotech, Bod Science (ASX:BOD), surged 12% this morning after prov...

2023 a case of “haves and have nots” for ASX biotech sector as companies with good catalysts lead the pack  Neuren’s results of Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome due in December Antisense Therapeutics Phase2b t...

Polynovo Ltd (ASX: PNV) shares have struggled to find support in 2023. After a brief reprieve between May and August, the wound treatment company has seen its share price slapped with a 22.3% decline over the last 29 days. On Friday, shar...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AIS)) - Aeris Resources ((AGI)) - Ainsworth Game Technology ((ALX)) - Atlas Arteria ((ATA)) - Atturra ((AUA)) - Audeara ((ASB)) - Austal ((BUB)) - Bubs Australia ((CCX))...

ASX healthcare stocks haven’t done so well as a collective over the past 12 months. The S&P/ASX 200 Health Care Index (ASX: XHJ) is down 8% over the past year. By comparison, the market benchmark S&P/ASX 200 Index (ASX: XJO) is u...

US healthcare company, CurveBeam AI, is preparing to debut on the ASX today after concluding its pre-initial public offering (IPO) private placement of $25 million. CurveBeam will be listed under the ticker code ‘CVB,’ providing investor...

ASX health stocks fall 2.4% in the past five days in line with broader markets Mesoblast crashes more than 50% after US FDA rejects a key product  ImpediMed falls after calls for board spill with discontent following cap raise Healthcare...

World Overnight SPI Overnight 7360.00 – 39.00 – 0.53% S&P ASX 200 7450.70 + 40.30 0.54% S&P500 4576.73 – 12.23 – 0.27% Nasdaq Comp 14283.91 – 62.11 – 0.43% DJIA 35630.68 + 71.15 0.20% S&P500 VIX 13.93 + 0.30 2.20%...

World Overnight SPI Overnight 7383.00 + 25.00 0.34% S&P ASX 200 7410.40 + 6.80 0.09% S&P500 4588.96 + 6.73 0.15% Nasdaq Comp 14346.02 + 29.37 0.21% DJIA 35559.53 + 100.24 0.28% S&P500 VIX 13.63 + 0.30 2.25% US 10...

Weekly update on stockbroker recommendation, target price, and earnings forecast changes. By Mark Woodruff Guide: The FNArena database tabulates the views of eight major Australian and international stockbrokers: Citi, Bell Potter, Macquari...

The S&P/ASX 200 Index (ASX: XJO) is on form again and on track to record a small gain. In afternoon trade, the benchmark index is up 0.2% to 7,340 points. Four ASX shares that have failed to follow the market higher today are listed...

The Energy sector demonstrated strong growth, with a rally of 1.7%. Ampol (ASX:ALD) experienced a significant surge of 4.4% following robust fuel sale volumes reported for the first half of the financial year 2023. Woodside Petroleum (ASX:W...

Woodside Energy (ASX:WPL), reported a 29% decline in revenue for the second quarter, amounting to $US3.1 billion (A$4.5 billion). Sales of oil decreased by 4%, with 48.4 million barrels sold, while production experienced a 5% drop to 44.5 m...

  ImpediMed (ASX:IPD) are the first top 5 national payor covering SOZO testing for cancer patients at risk for lymphoedema. In response, CEO and MD Richard Valencia said, ”Cigna’s policy provides access to coverage for all individuals at ri...

19 Jul 2023 - A snapshot of the stocks on the move, featuring ImpediMed (ASX:IPD), Imugene Limited (ASX:IMU) and Brightstar Resources (ASX:BTR).

Weekly update on stockbroker recommendation, target price, and earnings forecast changes. By Mark Woodruff Guide: The FNArena database tabulates the views of eight major Australian and international stockbrokers: Citi, Bell Potter, Macquari...

World Overnight SPI Overnight 7182.00 – 37.00 – 0.51% S&P ASX 200 7253.20 – 25.80 – 0.35% S&P500 4446.82 – 8.77 – 0.20% Nasdaq Comp 13791.65 – 25.12 – 0.18% DJIA 34288.64 – 129.83 – 0.38% S&P500 VIX 14.18 + 0.48 3....

World Overnight SPI Overnight 7233.00 – 12.00 – 0.17% S&P ASX 200 7279.00 + 32.90 0.45% S&P500 4455.59 Nasdaq Comp 13816.77 DJIA 34418.47 S&P500 VIX 13.70 US 10-year yield 3.86 USD Index 103.08 + 0.09...

World Overnight SPI Overnight 7216.00 – 1.00 – 0.01% S&P ASX 200 7246.10 + 42.80 0.59% S&P500 4455.59 + 5.21 0.12% Nasdaq Comp 13816.77 + 28.85 0.21% DJIA 34418.47 + 10.87 0.03% S&P500 VIX 13.57 – 0.02 – 0.15% US...

Clinical validation study confirms efficacy of INOVIQ’s SubB2M/CA15-3 test for breast cancer Ramsay releases several announcements this week including possible sale of joint Asian venture Mach 7 expects significant cash collections in Q4...

ShareCafeMiners surge on higher iron ore prices: ASX closes up 1% by Peter Milios   At the closing bell, the S&P/ASX 200 was 1.00 per cent higher at 7,216.30. The increase was driven by the mining and consumer discretionary sectors, whi...

ShareCafeAustralia’s inventories increase for March Qtr: ASX 1.05% higher at noon by Peter Milios   In the March quarter, Australia’s inventories increased by 1.2 per cent compared to the previous quarter, surpassing Bloomberg’s predicted 0...

ShareCafeStocks of the Hour: REZ, WA1, IPD                    Resources & Energy Group (ASX:REZ) announced that their opening drilling campaign has confirmed nickel sulphides at their Springfield Nickel Prospect in WA. MD and CEO,...

05 Jun 2023 - A snapshot of the stocks on the move featuring Resources & Energy Group (ASX:REZ), WA1 Resources (ASX:WA1) and ImpediMed (ASX:IPD).

ASX health stocks outperforming the broader market but remain flattish for week Several ASX health plays undertaking capital raising with more expected in H2 CY23 Micro-X successfully tests its Argus bomb detection unit opening door to US$...

The market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts that will push this momentum further? ASX biotechs that announced FDA breakthroughs this year   After a challenging 2022, we are finally s...

ASX health stocks have fallen in the past five days in line with broader markets Volpara Health Technologies reports strong FY23 results, above Morgan’s expectations Pharmaxis reports positive trial results in potential breakthrough treatm...

EBR announces positive results of its pivotal SOLVE-CRT trial at Heart Rhythm 2023 in US EBR latest ASX biotech company to achieve a key catalyst, opening door to US$2.5 billion market Company now working on regulatory and commercialisatio...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. At the time of writing, the benchmark index is up 0.6% to 7,278.9 points. Four ASX shares that have failed to follow the market high...

S&P/ASX 200 closes up 0.40%, while the emerging companies index rises 0.43% Algerian mining regulator issues a mining permit for Terramin’s Tala Hamza zinc-lead project Retail component of Next DC’s entitlement offer opens and is expec...